Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?

被引:24
作者
Oh, Kyu-Bin [1 ]
Doherty, T. Mark [2 ]
Vetter, Volker [3 ]
Bonanni, Paolo [4 ]
机构
[1] GSK, Wavre, Belgium
[2] GSK, Brondby, Denmark
[3] GSK, Munich, Germany
[4] Univ Florence, Dept Hlth Sci, Florence, Italy
关键词
COVID-19; pandemic; infectious diseases; influenza; non-pharmaceutical interventions; norovirus; outbreaks; respiratory syncytial virus; resurgence; rhinovirus; vaccine-preventable diseases; RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; SEASONAL INFLUENZA; DISEASE; IMPACT; IMMUNIZATION; INFECTIONS; CHILDHOOD; CHILDREN; TRANSMISSION;
D O I
10.1080/14760584.2022.2117693
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plain Language Summary In the first months of the COVID-19 pandemic, the only methods available to slow the spread of the disease were non-pharmaceutical interventions, such as lockdowns, mask wearing, social distancing, school closures, and travel bans. Even after vaccines against COVID-19 became available, combinations of non-pharmaceutical interventions continued to be implemented by most countries, to various extents. Although these measures lowered the number of people who got sick before vaccines and therapies against COVID-19 were available, they also had other consequences for public health. The non-pharmaceutical interventions implemented worldwide have slowed or even stopped the spread of several infectious diseases: since 2020, fewer cases of flu, bronchiolitis, gastroenteritis, and other diseases were recorded compared to pre-pandemic times. This relatively long 2-year period during which people, especially children, were exposed to fewer infections might mean that their immune systems are less prepared to fight these diseases. In addition, vaccination against diseases other than COVID-19 dropped in the early months of the pandemic, meaning that the number of children and adults who are not protected against vaccine-preventable disease has potentially increased. Easing of COVID-19 restrictions has caused a comeback of some diseases against which no vaccine is available, sometimes with more cases than during the pre-pandemic years; there is a risk that this might happen with vaccine-preventable diseases as well. To prevent outbreaks, routine and catch-up vaccinations against other diseases besides COVID-19 should be encouraged and promoted. Introduction In the first months of the novel coronavirus (COVID-19) pandemic that begun in 2020, non-pharmaceutical interventions (NPIs) have been adopted worldwide. However, the effects of NPI implementation go beyond slowing the spread of COVID-19. Here, we review the non-intended effects that may have arisen from prolonged application of NPIs. Areas covered NPIs also affected the epidemiology of other infectious diseases, with unprecedentedly low circulation of several respiratory and gastrointestinal viruses being observed worldwide in 2020. While this was a welcome effect for already strained health-care systems, prolonged low exposure to pathogens may result in an increased pool of individuals susceptible to certain diseases. Out-of-season or unusually intense outbreaks of non-vaccine preventable diseases have already been documented as NPIs were gradually eased. In the context of widespread and important disruptions in national vaccination programs during the early phase of the pandemic, the risk of vaccine-preventable disease resurgence after NPIs are lifted cannot be excluded either. Expert opinion Awareness must be raised of the risk of vaccine-preventable disease resurgence, and efforts need to be made to mitigate this risk, where possible, by increasing vaccination coverage. Research and regulatory opportunities brought on by the COVID-19 pandemic should be seized.
引用
收藏
页码:1541 / 1553
页数:13
相关论文
共 116 条
  • [71] Predicted norovirus resurgence in 2021-2022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study
    O'Reilly, Kathleen M.
    Sandman, Frank
    Allen, David
    Jarvis, Christopher, I
    Gimma, Amy
    Douglas, Amy
    Larkin, Lesley
    Wong, Kerry L. M.
    Baguelin, Marc
    Baric, Ralph S.
    Lindesmith, Lisa C.
    Goldstein, Richard A.
    Breuer, Judith
    Edmunds, W. John
    [J]. BMC MEDICINE, 2021, 19 (01)
  • [72] Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data
    Oh, Djin-Ye
    Buda, Silke
    Biere, Barbara
    Reiche, Janine
    Schlosser, Frank
    Duwe, Susanne
    Wedde, Marianne
    von Kleist, Max
    Mielke, Martin
    Wolff, Thorsten
    Duerrwald, Ralf
    [J]. LANCET REGIONAL HEALTH-EUROPE, 2021, 6
  • [73] Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021
    Olsen, Sonja J.
    Winn, Amber K.
    Budd, Alicia P.
    Prill, Mila M.
    Steel, John
    Midgley, Claire M.
    Kniss, Krista
    Burns, Erin
    Rowe, Thomas
    Foust, Angela
    Jasso, Gabriela
    Merced-Morales, Angiezel
    Davis, C. Todd
    Jang, Yunho
    Jones, Joyce
    Daly, Peter
    Gubareva, Larisa
    Barnes, John
    Kondor, Rebecca
    Sessions, Wendy
    Smith, Catherine
    Wentworth, David E.
    Garg, Shikha
    Havers, Fiona P.
    Fry, Alicia M.
    Hall, Aron J.
    Brammer, Lynnette
    Silk, Benjamin J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (10) : 3481 - 3486
  • [74] Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6
  • [75] OSullivan N., 2021, Ir Med J, V114, P269
  • [76] Our World in Data [Internet], 2021, COV 19 STRING IND
  • [77] A global agenda for older adult immunization in the COVID-19 era: A roadmap for action
    Privor-Dumm, Lois A.
    Poland, Gregory A.
    Barratt, Jane
    Durrheim, David N.
    Knoll, Maria Deloria
    Vasudevan, Prarthana
    Jit, Mark
    Bonvehi, Pablo E.
    Bonanni, Paolo
    [J]. VACCINE, 2021, 39 (37) : 5240 - 5250
  • [78] Simulation of four respiratory viruses and inference of epidemiological parameters
    Reis, Julia
    Shaman, Jeffrey
    [J]. INFECTIOUS DISEASE MODELLING, 2018, 3 : 23 - 34
  • [79] The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials
    Rid, Annette
    Lipsitch, Marc
    Miller, Franklin G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (03): : 219 - 220
  • [80] Changes in Seasonal Respiratory Illnesses in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic
    Rodgers, Loren
    Sheppard, Michael
    Smith, Amanda
    Dietz, Stephanie
    Jayanthi, Praveena
    Yuan, Yan
    Bull, Lara
    Wotiz, Samantha
    Schwarze, Tessa
    Azondekon, Roseric
    Hartnett, Kathleen
    Adjemian, Jennifer
    Kirking, Hannah L.
    Kite-Powell, Aaron
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 : S110 - S117